MX2023007780A - Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. - Google Patents
Terapia de combinacion usando un anticuerpo anti-fucosil-gm1.Info
- Publication number
- MX2023007780A MX2023007780A MX2023007780A MX2023007780A MX2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- fucosyl
- combination therapy
- subject
- lung cancer
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 229940124060 PD-1 antagonist Drugs 0.000 abstract 1
- 229940123751 PD-L1 antagonist Drugs 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 190000008236 carboplatin Chemical compound 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una terapia de combinación para tratar a un sujeto, tal como un sujeto afligido por cáncer de pulmón, tal como el cáncer de pulmón de células pequeñas, que comprende administrar al sujeto varias combinaciones de un anticuerpo anti-fucosil-GM1, un agente inmunomodulador, tal como un antagonista de PD-1/PD-L1, tal como un anticuerpo antagonista anti-PD-1 o anti-PD-L1, carboplatino y etopósido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135479P | 2021-01-08 | 2021-01-08 | |
| PCT/US2022/011564 WO2022150557A1 (en) | 2021-01-08 | 2022-01-07 | Combination therapy using an anti-fucosyl-gm1 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007780A true MX2023007780A (es) | 2023-07-10 |
Family
ID=80119207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007780A MX2023007780A (es) | 2021-01-08 | 2022-01-07 | Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240050564A1 (es) |
| EP (1) | EP4274850A1 (es) |
| JP (1) | JP2024503379A (es) |
| KR (1) | KR20230129467A (es) |
| CN (1) | CN116745322A (es) |
| AU (1) | AU2022205648A1 (es) |
| CA (1) | CA3204392A1 (es) |
| IL (1) | IL304200A (es) |
| MX (1) | MX2023007780A (es) |
| WO (1) | WO2022150557A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201912657D0 (en) * | 2019-09-03 | 2019-10-16 | Scancell Ltd | Binding members |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117534755A (zh) | 2005-05-09 | 2024-02-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| PL1960434T3 (pl) | 2005-12-08 | 2012-12-31 | Squibb & Sons Llc | Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| CN102245640B (zh) | 2008-12-09 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| EP2699264B1 (en) | 2011-04-20 | 2018-03-14 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US11104739B2 (en) * | 2016-04-14 | 2021-08-31 | Bristol-Myers Squibb Company | Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody |
| EP3463454A1 (en) * | 2016-06-03 | 2019-04-10 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer |
-
2022
- 2022-01-07 MX MX2023007780A patent/MX2023007780A/es unknown
- 2022-01-07 CN CN202280009378.0A patent/CN116745322A/zh active Pending
- 2022-01-07 EP EP22702075.7A patent/EP4274850A1/en active Pending
- 2022-01-07 WO PCT/US2022/011564 patent/WO2022150557A1/en active Application Filing
- 2022-01-07 JP JP2023541613A patent/JP2024503379A/ja active Pending
- 2022-01-07 US US18/271,579 patent/US20240050564A1/en active Pending
- 2022-01-07 CA CA3204392A patent/CA3204392A1/en active Pending
- 2022-01-07 KR KR1020237026366A patent/KR20230129467A/ko unknown
- 2022-01-07 AU AU2022205648A patent/AU2022205648A1/en active Pending
-
2023
- 2023-07-03 IL IL304200A patent/IL304200A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230129467A (ko) | 2023-09-08 |
| CN116745322A (zh) | 2023-09-12 |
| AU2022205648A1 (en) | 2023-08-24 |
| JP2024503379A (ja) | 2024-01-25 |
| US20240050564A1 (en) | 2024-02-15 |
| EP4274850A1 (en) | 2023-11-15 |
| WO2022150557A1 (en) | 2022-07-14 |
| IL304200A (en) | 2023-09-01 |
| CA3204392A1 (en) | 2022-07-14 |
| AU2022205648A9 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| BR112018070636A2 (pt) | método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| PH12018502409A1 (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| NZ769968A (en) | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy | |
| MX2021000100A (es) | Inhibidores de muerte programada-1 (pd-1)/ ligando de muerte programada 1 (pd-l1). | |
| AU2017228470A8 (en) | Combination therapy with anti-CD73 antibodies | |
| CR20190478A (es) | Inhibidores de pd-1/pd-l1 | |
| JOP20220163A1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| EA202190181A1 (ru) | Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1 | |
| MX2018013354A (es) | Terapia de combinacion para tratamiento de cancer. | |
| WO2016029073A3 (en) | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody | |
| MX2024006614A (es) | Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer. | |
| WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
| EP4386005A3 (en) | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer | |
| MX2019002728A (es) | Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres. | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| WO2022060986A3 (en) | Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy | |
| MX2023007780A (es) | Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. | |
| MX2020014091A (es) | Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii. | |
| MX2021000558A (es) | Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino. | |
| MX2023003186A (es) | Regimenes de dosificacion de anticuerpo anti-ilt4 o su combinacion con anticuerpo anti-pd-1 para el tratamiento de cancer. |